Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 7, 2016; 22(41): 9141-9153
Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9141
Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9141
Figure 4 Combined effects of HER2 silencing and JNK inhibition on metastatic potential.
SNU-216 and NCI-N87 cells were infected with a lentivirus containing either control shRNA (shCtrl) or HER2 shRNA (shHER2) followed by treatment with either DMSO or SP600125 (SP). A, D: After treatment with SP for 24 h, protein expressions of pHER2 and pJNK were determined by Western blot; B, E: After treatment with SP for 48 h, cell migration was evaluated by Transwell migration assay; C, F: After treatment with SP for 48 h, invasion was evaluated by cell invasion assay. Results were calculated as percentages relative to control cells. Data are expressed as mean ± SD (n = 4 per each group). aP < 0.05 vs control cells.
- Citation: Choi Y, Ko YS, Park J, Choi Y, Kim Y, Pyo JS, Jang BG, Hwang DH, Kim WH, Lee BL. HER2-induced metastasis is mediated by AKT/JNK/EMT signaling pathway in gastric cancer. World J Gastroenterol 2016; 22(41): 9141-9153
- URL: https://www.wjgnet.com/1007-9327/full/v22/i41/9141.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i41.9141